|
|
2010 Euro-Biotech Forum
Please Check Back Often for Schedule Updates!
| June 28, 2010 |
6:00-7:30PM |
Welcome Reception & Registration |
| June 29, 2010 |
7:30-8:15AM |
Registration / Welcome Coffee |
| 8:15-8:20AM |
Welcome and Introductory Remarks |
| 8:20-9:00AM |
Keynote Session
Fireside Chat with Special Guest
Jonathan Peacock
Chief Financial & Administration Officer
Novartis Pharma |
9:00-5:30PM |
Company Presentations
- 1) TOP BIOTECH COMPANIES TO WATCH
Nominees are companies with unpartnered preclinical or clinical stage assets (or platforms with potential for broad pharma deals). These assets or platforms should have applications in one or more specific therapeutic spaces of interest to pharmaceutical partners.
Specifically:
- Most valuable assets
- All phases
- Large market, large unmet need, with increasing opportunity
- History of the molecule and drug
- Strong science
- Strong company
- Diversity of indications
- Potential for new opportunities beyond the initial indications
- Multi-level partnering opportunities, i.e., biotech to biotech as well as pharma to biotech
- 2) Top Partners of Choice
- 3) Best Biotech Investors
|
| 9:00-9:15AM |
Pfizer |
One-on-One Partnering Meetings |
| 9:15-9:30AM |
UCB |
| 9:30-9:45AM |
Merck and Co, Inc. |
| 9:45-10:00AM |
Merck Serono |
| 10:00-10:15AM |
Calistoga Pharmaceuticals |
| 10:15-10:30:AM |
Bristol-Myers Squibb |
10:30-10:45AM |
Almirall |
| 10:45-11:00AM |
Roche |
| 11:00-11:15AM |
Aisling Capital |
| 11:15-11:30AM |
Abingworth LLP |
| 11:30-11:45AM |
Index Ventures |
| 11:45-12:00PM |
Boehringer Ingelheim |
| 12:00-12:15PM |
Daiichi-Sankyo |
| 12:15-12:30PM |
|
12:30-1:30PM |
Networking Luncheon |
| 1:30-2:15PM |
Special Keynote Session
Spotlight on Teva Pharma: Balancing Organic and External Growth
Even as most of pharma sees Europe as a mature market ridden with pricing pressures, Teva Pharma, by far the world’s largest and most successful generics manufacturer, is unabashedly targeting the region as an opportunity. In a keynote presentation, Teva Pharma Europe CEO Gerard van Odijk, MD, will discuss how the firm plans to balance organic and external growth (through M&A and licensing) as a response to Europe’s rapidly changing pharma environment. Before joining Teva in 2006, Mr. van Odik held a variety of senior management positions in Europe at GlaxoSmithKline and was most recently SVP, GSK Northern Europe.
Gerard WM van Odijk
President & CEO
Teva Pharmaceuticals Europe B.V.
|
| 2:15-2:30PM |
Chroma Therapeutics |
One-on-One Partnering Meetings |
| 2:30-2:45PM |
Concert Pharma |
| 2:45-3:00PM |
Evolva |
| 3:00-3:15PM |
Ablynx NV |
| 3:15-3:30PM |
Intercell |
| 3:30-3:45PM |
KAI Pharmaceuticals |
| 3:45-4:00PM |
Allon Therapeutics |
| 4:00-4:15PM |
Protaffin |
| 4:15-4:30PM |
Transgene |
| 4:30-4:45PM |
Vantia Therapeutics |
| 4:45-5:00PM |
Movetis |
| 5:00-5:15PM |
Dicerna |
| 5:15-5:30PM |
VentiRx |
| 5:30-5:45PM |
Seattle Genetics |
6:00-8:00PM |
Cocktail Reception |
| June 30, 2010 |
7:30-8:15AM |
Registration / Welcome Coffee |
8:15AM |
Welcome and Day 1 Recap |
8:15-9:15AM |
Deals in Depth: Understanding the Rationale Driving The Year's Most Strategically Interesting Alliances
Whether licensing or acquisition, global or regional, structuring deals to spread risk and reward has rarely if ever been more of an exercise in creativity than it is today. We’ve chosen three deals across a broad spectrum of strategic initiatives that provide case studies for this new, creative dealmaking environment. Each has a European flavour, and of course there are options, earn-outs and carve-outs galore. We’ll discuss deal-specific and broader questions, including how Ipsen’s combined out-licensing/equity stake/option arrangement with Inspiration fits into the French pharma’s unique approach to specialty franchise building; AstraZeneca’s and Forest’s creative collaboration to gain full access to Novexel’s antibiotic pipeline, and, amid a flurry of late-stage asset acquisitions, why AZ chose Targacept’s nicotinic channel blocker for major depressive disorder to enter into one of the riches alliances in recent memory. This panel will look at the impact of these exemplary transactions and deal structures on the participants’ broader strategies and alliance/M&A transactions more globally going forward.
Robert J. Easton, Chairman, Scisive Consulting LP (moderator)
Ipsen/Inspiration
Jean-Luc Belingard, Chairman and CEO, Ipsen
AZ/Targacept
Beth Fordham-Meier, Vice President, Licensing and Intellectual Property, Targacept
GSK/Prosensa
Luc Dochez, Chief Business Officer and SVP of Business Development, Prosensa
Fran Heller, Executive Vice President of Business Development,
Exelixis |
9:15-10:00AM |
Project Financing: Meet Big Pharma’s Biggest Dealmaking Competitors
Asset-focused financing strategies have typically focused on getting later stage assets past crucial value inflection points. But today’s project financiers are branching out, and devising risk-sharing deal structures and strategies designed to enhance the value proposition for products at all stages of the value chain. What’s more there are now more seekers of project financing: from Big Pharma through the smallest start-ups, the demand for non-dilutive project financing is strong.
On this panel we’ll hear from dealmakers and financiers with experience in a variety of asset-focused deals and learn about evolving deal structures and strategies designed to spread risk and boost reward.
Richard Smith, Partner Life Science Practice, Edwards Angell Palmer & Dodge, LLP (moderator)
- Stephen Parker, PhD, Partner, Celtic Pharma
- Ken Macleod, Ph.D., Partner, Paul Capital Partners
- William Robb, Vice President, Capital Solutions, Quintiles
- Allan Marchington, PhD, Partner, Apposite Capital LLP
- Michael Nowak, Yorkville Advisors, LLC, Managing Director
|
10:00-1:00PM |
Company Presentations |
10:00-10:15AM |
SR One |
One-on-One Partnering Meetings |
| 10:15-10:30AM |
Cowen Healthcare Royalty Partners |
| 10:30-10:45AM |
Amgen |
| 10:45-11:00AM |
Bayer Schering Pharma |
| 11:00-11:15AM |
Novartis |
| 11:15-11:30AM |
Celtic Therapeutics |
| 11:30-11:45AM |
MPM Capital |
| 11:45-12:00PM |
Roche Venture Fund |
| 12:00-12:15PM |
Sofinnova Partners |
| 12:15-12:30PM |
Antisoma plc |
| 12:30-12:45PM |
f-star |
| 12:45-1:00PM |
Heptares |
| 1:00-1:15PM |
Topotarget |
1:15 |
To-Go Lunch - Normandie Foyer |
| Legend |
| |
Company Presentations |
| |
Plenary Session |
| |
One-on-One Partnering Meetings |
| |
Keynote/Fireside Chat |
Click on a speaker name to view their bio |
|
|
|